Amneal Pharmaceuticals Inc. Class A

4.16-0.2000-4.59%Vol 1.29M1Y Perf 31.19%
Oct 30th, 2020 16:00 DELAYED
BID4.15 ASK4.30
Open4.35 Previous Close4.36
Pre-Market- After-Market-
 - -%  - -%
Target Price
4.43 
Analyst Rating
Hold 2.78
Potential %
6.49 
Finscreener Ranking
★+     44.20
Insiders Trans % 3/6/12 mo.
-/100/100 
Value Ranking
★★     47.55
Insiders Value % 3/6/12 mo.
-/100/100 
Growth Ranking
     34.44
Insiders Shares Cnt. % 3/6/12 mo.
-/100/100 
Income Ranking
 —    -
Market Cap1.25B 
Earnings Rating
Buy
Price Range Ratio 52W %
51.92 
Earnings Date
6th Nov 2020

Today's Price Range

4.154.39

52W Range

2.405.79

Summary:

Sell

Technical Indicators: Sell
Moving Averages: Strong Sell
Performance
1 Week
-20.15%
1 Month
7.22%
3 Months
-3.26%
6 Months
14.60%
1 Year
31.19%
3 Years
-77.08%
5 Years
-87.99%
10 Years
-77.92%

TickerPriceChg.Chg.%
AMRX4.16-0.2000-4.59
AAPL108.86-6.4600-5.60
GOOG1 621.0153.77003.43
MSFT202.47-2.2500-1.10
XOM32.62-0.3500-1.06
WFC21.450.31001.47
JNJ137.11-0.0800-0.06
FB263.11-17.7200-6.31
GE7.420.05000.68
JPM98.040.87000.90
Earnings HistoryEstimateReportedSurprise %
Q02 20200.100.100.00
Q01 20200.070.18157.14
Q04 20190.030.07133.33
Q03 20190.120.00-100.00
Q02 20190.140.06-57.14
Q01 20190.180.11-38.89
Q04 20180.260.3223.08
Q03 20180.250.264.00
Earnings Per EndEstimateRevision %Trend
9/2020 QR0.129.09Positive
12/2020 QR0.138.33Positive
12/2020 FY0.555.77Positive
12/2021 FY0.696.15Positive
Next Report Date6th Nov 2020
Estimated EPS Next Report0.12
Estimates Count4
EPS Growth Next 5 Years %-
Volume Overview
Volume1.29M
Shares Outstanding299.66M
Trades Count5.71K
Dollar Volume6.18M
Avg. Volume1.57M
Avg. Weekly Volume1.38M
Avg. Monthly Volume1.30M
Avg. Quarterly Volume1.16M

Amneal Pharmaceuticals Inc. Class A (NYSE: AMRX) stock closed at 4.16 per share at the end of the most recent trading day (a -4.59% change compared to the prior day closing price) with a volume of 1.29M shares and market capitalization of 1.25B. Is a component of indices and it is traded on NYSE exchange. The company belongs in the Drug Manufacturers industry, Healthcare sector and employs 6000 people. Amneal Pharmaceuticals Inc. Class A CEO is Chintu Patel / Chirag Patel.

The one-year performance of Amneal Pharmaceuticals Inc. Class A stock is 31.19%, while year-to-date (YTD) performance is -13.69%. AMRX stock has a five-year performance of -87.99%. Its 52-week range is between 2.4 and 5.79, which gives AMRX stock a 52-week price range ratio of 51.92%

Amneal Pharmaceuticals Inc. Class A currently has a PE ratio of -, a price-to-book (PB) ratio of 2.51, a price-to-sale (PS) ratio of 0.56, a price to cashflow ratio of 2.30, a PEG ratio of 2.32, a ROA of -4.70%, a ROC of -2.42% and a ROE of -51.11%. The company’s profit margin is 3.66%, its EBITDA margin is 19.70%, and its revenue ttm is $1.36 Billion , which makes it $9.22 revenue per share.

Of the last four earnings reports from Amneal Pharmaceuticals Inc. Class A, there were 2 positive earnings surprise and 1 negative earnings surprise. The company has EPS estimate of $0.12 for the next earnings report. Amneal Pharmaceuticals Inc. Class A’s next earnings report date is 06th Nov 2020.

The consensus rating of Wall Street analysts for Amneal Pharmaceuticals Inc. Class A is Hold (2.78), with a target price of $4.43, which is +6.49% compared to the current price. The earnings rating for Amneal Pharmaceuticals Inc. Class A stock is Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).

Amneal Pharmaceuticals Inc. Class A has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.

Amneal Pharmaceuticals Inc. Class A has a Sell technical analysis rating based on Technical Indicators (ADX : 29.23, ATR14 : 0.29, CCI20 : -109.85, Chaikin Money Flow : -0.24, MACD : 0.07, Money Flow Index : 46.82, ROC : -17.46, RSI : 38.04, STOCH (14,3) : 0.74, STOCH RSI : 0.00, UO : 28.32, Williams %R : -99.26), Simple Moving Averages and Exponential Moving Averages.

Aggregated Insider Trades of Amneal Pharmaceuticals Inc. Class A in the last 12-months were: Andrew S. Boyer (Option Excercise at a value of $0), Boyer S Andrew (Option Excercise at a value of $0), Chintu Patel (Buy at a value of $2 567 884), Chintu Patel (Option Excercise at a value of $0), Chirag Patel (Buy at a value of $2 567 916), Chirag Patel (Option Excercise at a value of $0), David A. Buchen (Option Excercise at a value of $0), Emily Peterson Alva (Option Excercise at a value of $0), Gautam Patel (Buy at a value of $589 073), Gautam Patel (Option Excercise at a value of $0), J. Kevin Buchi (Option Excercise at a value of $0), Jeffrey P. George (Buy at a value of $99 050), John J. Kiely (Buy at a value of $44 000), Joseph Todisco (Buy at a value of $144 800), Joseph Todisco (Option Excercise at a value of $0), Nikita Shah (Option Excercise at a value of $0), Paul M. Meister (Buy at a value of $970 344), Paul M. Meister (Option Excercise at a value of $0), Peter R. Terreri (Option Excercise at a value of $0), Ted C. Nark (Option Excercise at a value of $0), Todd P. Branning (Option Excercise at a value of $0)

Analyst RatingsCurrent1 M ago3 M ago
Strong Buy
2 (22.22 %)
2 (20.00 %)
2 (18.18 %)
Moderate Buy
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Hold
6 (66.67 %)
7 (70.00 %)
7 (63.64 %)
Moderate Sell
0 (0.00 %)
0 (0.00 %)
0 (0.00 %)
Strong Sell
1 (11.11 %)
1 (10.00 %)
2 (18.18 %)
Summary RatingHold
2.78
Hold
2.80
Hold
3.00

Amneal Pharmaceuticals Inc. Class A

Amneal Pharmaceuticals Inc is a generic pharmaceutical manufacturer. The company's reportable segments are Generic Products and Specialty products. Generics segment develops, manufactures and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals, and Specialty segment is engaged in the development, promotion, sale and distribution of proprietary branded pharmaceutical products. It generates a majority of its revenue from the Generic business segment.

CEO: Chintu Patel / Chirag Patel

Teplephone: +1 908 947-3120

Address: 400 Crossing Boulevard, Bridgewater 08807, NJ, USA

Number of employees: 6 000

Bearish or Bullish?
WeekMonthThree MonthsSix Months

Bearish Bullish

50%50%

Bearish Bullish

100%0%

Bearish Bullish

75%25%

Bearish Bullish

33%67%

News

Stocktwits